
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ent001
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Enthera Pharmaceuticals Initiates Phase 1 Clinical Trial with Lead Candidate Ent001
Details : Ent001 targets the TMEM219 ligand, IGFBP3, it is designed to bind to TMEM219 and prevent cell death and the inflammation in type 1 diabetes and several other autoimmune diseases.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 07, 2023
Lead Product(s) : Ent001
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ent001
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Roche Venture Fund
Deal Size : $42.3 million
Deal Type : Series A Financing
Enthera Pharmaceuticals Extends Series A Financing, Raising a Total Of €35m
Details : The proceeds from the Series A financing will be used to obtain clinical proof-of-concept through a first-in-human study of Ent001, Enthera’s lead candidate.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
January 28, 2021
Lead Product(s) : Ent001
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Roche Venture Fund
Deal Size : $42.3 million
Deal Type : Series A Financing

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ent001
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Sofinnova Partners
Deal Size : $33.1 million
Deal Type : Series A Financing
Details : Proceeds to be used for clinical proof-of-concept for lead product Ent001 (IGFBP3/TMEM219 inhibitor) for type 1 diabetes, gastrointestinal diseases and progress pipeline assets.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
July 28, 2020
Lead Product(s) : Ent001
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Sofinnova Partners
Deal Size : $33.1 million
Deal Type : Series A Financing
